HomeBUSINESS
BUSINESS

VLP Flu Vaccine Enters PIII in North America, Europe: Mitsubishi Tanabe
(Sep.28.2017)

Mitsubishi Tanabe Pharma said on September 27 that its Canadian subsidiary Medicago has commenced a PIII clinical study of its seasonal quadrivalent influenza vaccine in the US, Canada, Europe, and Asia. The vaccine is being developed based on the Canadian firm’s plant-derived virus like particle (VLP) production technologies ...
(LOG IN FOR FULL STORY)

News Calendar